Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cann Group ( (AU:CAN) ).
Cann Group Limited has received a Letter of Non-Waiver from National Australia Bank regarding its non-payment of interest and facility fees totaling $1,378,152, which were due in late August 2025. While NAB reserves its rights, it has decided not to take any action at this time. Cann Group is actively engaging with NAB and other financiers to address its financing arrangements and plans to update the market by the end of September 2025.
More about Cann Group
Cann Group Limited is a company focused on enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. It operates research facilities and a large-scale cultivation and GMP manufacturing facility in Victoria, Australia, and supplies a range of cannabis products and pharmaceutical ingredients globally. The company also owns Satipharm, known for its patent-protected capsule technology.
YTD Price Performance: -66.67%
Average Trading Volume: 1,305,733
Technical Sentiment Signal: Sell
Current Market Cap: A$8.63M
Find detailed analytics on CAN stock on TipRanks’ Stock Analysis page.